Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer.
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), Julius Strauss(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Colin C. Pritchard(Animal and Plant Health Agency), Fatima Karzai(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), Philip M. Arlen(Dana-Farber Cancer Institute), Houssein Abdul Sater(National Institutes of Health), Anna Couvillon(National Institutes of Health), Myrna Rauckhorst(National Institutes of Health), Monique Williams(National Institutes of Health), William L. Dahut(National Cancer Institute)
Cited by 1
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
|New England Journal of Medicine|2016|1.6k